Should Patents On REMS Distribution Restrictions Be Banned?
This article was originally published in The Pink Sheet Daily
Executive Summary
Citing the use of Risk Evaluation and Mitigation Strategies to delay generic entry, Boston researchers urge Congress to revisit an “unintended consequence” created by the 2007 FDA Amendments Act.
You may also be interested in...
FDA Re-Evaluates Orange Book Patents
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
US FDA Mulls ‘Orange Book’ Listing For Device, REMS, Digital App Patents
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
REMS Modification Guidance Coming As FDA Rejects Petition For Shared REMS Rules
Agency will wait until it has more experience with shared REMS before deciding whether to issue regulations or guidance on their implementation, but for now it hopes sponsors can work out problems on their own.